RabMAbs against Post Translational Modifications
Rabbits have a unique immune system which allows them to develop antibodies against “small epitopes” present in small molecules, lipids and polymers or subtle changes in epitopes such as post-translational modifications or single amino acid substitutions. RabMAbs offer high affinity and specificity to the modified target with minimal cross-reactivity to the non-modified site. Having generated more than 350 post-translational modification specific antibodies, and with many more in the pipeline, Epitomics has the experience to help you develop modification-specific antibodies according to your needs.
RabMAbs against Histone H3 Modifications |
||
|---|---|---|
Methylation |
Acetylation |
Phosphorylation |
 |
 |
 |
Western blot analysis using anti-Histone H3 Dimethyl (K4)RabMAb (cat. #1347-1). Lane (1) Hela cell lysate; lane (2) recombinant Histone H3 (non-methylated) |
Western blot analysis on C6 cell lysate using anti-Histone H3 Acetyl-K56 RabMAb (cat. # 2134-1),Lane (1) untreated; lane (2) treated with TSA |
Western blot analysis on NIH 3T3 cell lysate using anti-Phospho-Histone H3 (pS28) RabMAb (cat.#1329-1); Lane (1) untreated; lane (2) treated with FBS and Calyculin A |
Phospho Specific RabMAbs |
|||
|---|---|---|---|
Phosphotyrosine (pY) |
Phosphoserine (pS) |
Phosphothreonine (pT) |
Dual Phospho (pT/pS) |
 |
 |
 |
 |
Western blot analysis on A431 cell lysates using anti-Phospho-EGFR (pY1110) RabMAb (cat #2284-1), Lane 1 untreated; Lane 2 treated with EGF |
Western blot analysis on NIH 3T3 cell lysate using anti-Phospho-c-Jun (pS63) RabMAb (cat #1527-1), Lanes 1 and 3, untreated; lane 2 and 4,treated with UV or Anisomycin, respectively |
Western blot analysis on Jurkat cell lysate using anti-Phospho-p70S6 Kinase (pT389)RabMAb (cat. #1175-1); Lane 1, serum starved; Lane 2 treated with FBS |
Western blot analysis on 293T cell lysate using anti-Phospho-p70 S6 Kinase (pT421/pS424) RabMAb (cat. #1135-1); Lane 1, untreated; Lane 2, treated with EGF |
